

Reference Number: FOI202223/028
From: Commercial
Date: 13 April 2022
Subject: Numbers of and use of new biologic medications within dermatology

Q1 I am analysing the usage of new biologic medications within dermatology. Could you please tell me how many patients were treated in March 2022 (or latest available month) by the dermatology department with the following drugs:

- a. Abrocitinib (Cibinqo)
- b. Baricitinib (Olumiant)
- c. Bimekizumab (Bimzelx)
- d. Brodalumab (Kyntheum)
- e. Dupilumab (Dupixent)
- f. Ixekizumab (Taltz)
- g. Risankizumab (Skyrizi)
- h. Guselkumab (Tremfya)
- i. Secukinumab (Cosentyx)
- j. Tildrakizumab (Ilumetri)
- k. Tralokinumab (Adtralza)
- l. Upadacitinib (Rinvoq)
- m. Ustekinumab (Stelara)

- A1**
- a. Zero
 - b. Zero
 - c. Zero
 - d. Zero
 - e. 10
 - f. Zero
 - g. Zero
 - h. Zero
 - i. Zero
 - j. Zero
 - k. Zero
 - l. Zero
 - m. Zero